Equity Profile

BIO

Bio-Rad Laboratories, Inc.

Health CareLife Sciences Tools & Services$8.7B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Bio-Rad Laboratories, Inc. is a key player in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well Bio-Rad is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is vital for assessing the company's market demand and overall business health, especially in the competitive life sciences field.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BIO Q2-2026 Earnings Preview

Context

Company Snapshot

Bio-Rad Laboratories, Inc. is a key player in the health care sector, specializing in life sciences tools and services. The company provides essential products and solutions for research and clinical diagnostics, making it significant in the ongoing advancements in health care and biotechnology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+15.34%

Avg Stock Reaction

-1.01%

Last Quarter Recap

In Q1-2026, Bio-Rad reported an EPS of $1.89, which was significantly below the expected $2.77, resulting in a 31.77% negative surprise. Following the announcement, the stock saw a modest increase of 1.81% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts have mixed expectations for Bio-Rad's upcoming earnings report, especially after a disappointing Q1. Investors will be closely watching for any signs of recovery or continued struggles.

Bull Case

If Bio-Rad can exceed EPS expectations and show strong revenue growth, it could signal a turnaround and renewed investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company reports another earnings miss, it may indicate deeper issues within the business, leading to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be this quarter, and will it meet or exceed expectations?

Given the significant EPS miss last quarter, investors are eager to see if Bio-Rad can recover and provide a positive surprise.

How is revenue growth trending in key segments?

Understanding revenue trends will help gauge the company's market position and demand for its products, which is crucial for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Rad's potential for recovery, as the recent EPS miss could be attributed to temporary factors rather than fundamental weaknesses.

Supporting Evidence

Options are pricing a 17.11% move, indicating expectations of volatility that may not align with the company's actual performance.

The historical average move post-earnings has been much lower, suggesting that the market may be overreacting.

Bio-Rad has a history of bouncing back after earnings misses, which could lead to a surprise this quarter.

Key Risk

If the EPS comes in above $2.00, it could significantly shift market sentiment and challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for Bio-Rad to demonstrate its ability to rebound from recent earnings misses and regain investor confidence.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating a strong recovery.

Bear Confirmed If

An EPS below $1.50 would support the bear case, suggesting ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±17.11%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move of over 17%, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±17.1% while BIO has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

58.0%

Calls (2K)P/C Ratio: 0.33Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Rad beats expectations, history suggests the stock could see a modest increase, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience limited movement as investors await more clarity from management.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 0.97%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the pipeline.
2Management's commentary on cost management strategies and their impact on profitability.
3Insights into market demand for Bio-Rad's key products and services.
4Any guidance on revenue expectations for the upcoming quarters.
5Responses to questions about competitive pressures and market positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Bio-Rad Laboratories, Inc. is a key player in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well Bio-Rad is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is vital for assessing the company's market demand and overall business health, especially in the competitive life sciences field.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+15.34%

Avg Stock Reaction

-1.01%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts have mixed expectations for Bio-Rad's upcoming earnings report, especially after a disappointing Q1. Investors will be closely watching for any signs of recovery or continued struggles.

Bull Case

If Bio-Rad can exceed EPS expectations and show strong revenue growth, it could signal a turnaround and renewed investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company reports another earnings miss, it may indicate deeper issues within the business, leading to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be this quarter, and will it meet or exceed expectations?

Given the significant EPS miss last quarter, investors are eager to see if Bio-Rad can recover and provide a positive surprise.

How is revenue growth trending in key segments?

Understanding revenue trends will help gauge the company's market position and demand for its products, which is crucial for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Rad's potential for recovery, as the recent EPS miss could be attributed to temporary factors rather than fundamental weaknesses.

Supporting Evidence

Options are pricing a 17.11% move, indicating expectations of volatility that may not align with the company's actual performance.

The historical average move post-earnings has been much lower, suggesting that the market may be overreacting.

Bio-Rad has a history of bouncing back after earnings misses, which could lead to a surprise this quarter.

Key Risk

If the EPS comes in above $2.00, it could significantly shift market sentiment and challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for Bio-Rad to demonstrate its ability to rebound from recent earnings misses and regain investor confidence.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating a strong recovery.

Bear Confirmed If

An EPS below $1.50 would support the bear case, suggesting ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±17.11%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move of over 17%, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±17.1% while BIO has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

58.0%

Calls (2K)P/C Ratio: 0.33Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Rad beats expectations, history suggests the stock could see a modest increase, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience limited movement as investors await more clarity from management.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 0.97%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the pipeline.
2Management's commentary on cost management strategies and their impact on profitability.
3Insights into market demand for Bio-Rad's key products and services.
4Any guidance on revenue expectations for the upcoming quarters.
5Responses to questions about competitive pressures and market positioning.